Last reviewed · How we verify
NCT05517356
Prospective Study of Tailored Management Strategies for Malperfusion Syndrome
NA trial testing Tailored management strategies in Aortic Dissection in 120 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Xiamen Cardiovascular Hospital, Xiamen University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 January 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tailored management strategies
Conditions studied
- Aortic Dissection — all drugs for Aortic Dissection →
Sponsor
Xiamen Cardiovascular Hospital, Xiamen University
Who can join
Adults 18 to 80, any sex, with Aortic Dissection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Management strategy of malperfusion syndrome in acute type A aortic dissection (ATAAD) patients remains controversial, with different views on when the surgery should be offered. At present, the mortality of ATAAD patients complicated with malperfusion is stubbornly high. The purpose of this study is to improve the outcomes of ATAAD with malperfusion syndrome. The investigators formulated tailored management strategies for malperfused patients based on the duration of symptoms onset.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05517356
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Dissection
Currently open trials in the same condition.
- NCT06550986 — False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study · NA · recruiting
- NCT06968806 — Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection · Phase 3 · recruiting
- NCT06827990 — GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections · NA · recruiting
- NCT06915545 — Study on the Aortic Arch Single Branch Stent Graft System · NA · recruiting
- NCT07117825 — Aortic Dissection fAlse enlarGement radIomics predictiOn · active not recruiting
Other Xiamen Cardiovascular Hospital, Xiamen University trials
Trials by the same sponsor.
- NCT07055919 — Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER). · NA · recruiting
- NCT06532838 — Optimized Strategies for Malperfusion Syndrome · NA · not yet recruiting
- NCT05925335 — The China Mviv Registry · NA · unknown
- NCT05497141 — Dawneo Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System Pivotal Clinical Trial in Patients With Sever · NA · unknown
- NCT04918030 — STaged Interventional Strategies for Acute ST-seGment Elevation Myocardial Infarction Patient With Multi-vessel Disease（ · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05517356 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiamen Cardiovascular Hospital, Xiamen University
- Last refreshed: 26 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05517356.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing